ClinicalTrials.gg
Sign In

BiologicalDrug

Anti-ILT4 Monoclonal Antibody MK-4830 clinical trials

Also written MK-4830.

studies test it
4
open now
0
in phase 3
0
first study started
2018

How studies write it

Studies that test it under each name

Development codes

MK-4830
3

Combined with it in one product

MK-4830 + Pembrolizumab
1

Studies by the year they started

4 studies that test it; most in 2022 (2)

Studies that test Anti-ILT4 Monoclonal Antibody MK-4830, by start year
YearStudies
20181
20211
20222

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
2
Phase 2
2

What it is tested for

Each study’s main condition, where its own words name it.

Small Cell Lung Carcinoma
1
Neoplasms
1
Ovarian Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1

Who runs them

Industry 4 · Other 0

Merck Sharp & Dohme LLC (3) · Presage Biosciences (1)

Often tested with

Tested in the same studies.

Pembrolizumab (2) · Pembrolizumab/Quavonlimab MK-1308A (1) · Lenvatinib (1) · Favezelimab/Pembrolizumab Formulation (1) · Raludotatug deruxtecan (1) · MK-4830A (1) · Rolistobart (1)

Studies

Open first, then newest update. How each study uses Anti-ILT4 Monoclonal Antibody MK-4830 is read from its arms, and is right about nine times in ten.

Testing it · 4

Given in every arm · 9 — Anti-ILT4 Monoclonal Antibody MK-4830 is usual care beside what is tested